Navigation Links
Keystone Nano Announces Progress On RNA Delivery
Date:4/11/2017

STATE COLLEGE, Pa., April 11, 2017 /PRNewswire/ -- Keystone Nano, Inc. (KN), a clinical stage biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today significant progress on the delivery of RNA using NanoJackets (NJs).  KN's NanoJackets are proprietary, customizable calcium phosphate nanoparticles that protect the active agent in the bloodstream and deliver it to targeted cells.  Key recent achievements include:

  • substantial new knowledge on encapsulating various kinds of RNA including siRNA, micro RNA and messenger RNA,
  • improved knowledge about the safety/toxicity of the NanoJacketed RNA,
  • new understanding of bio-distribution after administration by injection or inhalation, and
  • greater knowledge about the length of time RNA-NanoJackets work within the body

KN is working to optimize the therapeutic activity of RNA both for the internal programs and for pharmaceutical client companies.  KN has found that working with NanoJackets to encapsulate and deliver the different types of RNA requires different approaches for each.  However, in all cases, KN's RNA-NanoJackets have shown that they contain substantial amounts of RNA, are composed of safe and well tolerated materials, protect the RNA from degradation in the blood stream and can be targeted to specific cell types.

Several new breakthrough therapies anticipate using the different types of RNA to halt disease progression – either by silencing select RNA processes associated with disease, or by using RNA to code for production of therapeutic molecules within the body itself.  The increasing interest in RNA therapy has led to a need for a safe, effective and efficient method to deliver RNA.  KN's calcium phosphate NanoJackets offer a highly biocompatible, non-toxic and effective solution to that problem.

KN's work in RNA delivery has been supported by grants from the National Cancer Institute, the National Institute for Allergies and Infectious Diseases, and the Pennsylvania Department of Health.  KN's work in RNA delivery builds on work at Penn State and the University of Virginia. Jeff Davidson, KN's CEO, noted: "our research team has made great progress building powerful new ways to deliver RNA.  Our goal is to continue this work to further improve human health."

About Keystone Nano, Inc.  KNs lead product, Ceramide NanoLiposome, entered clinical testing in early 2017.  For more information visit www.keystonenano.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/keystone-nano-announces-progress-on-rna-delivery-300437963.html


'/>"/>
SOURCE Keystone Nano, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
2. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
3. MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
4. University City Keystone Innovation Zone Expands to Old City, N3rd Street Startup Community
5. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
6. Greater Gift Initiative Announces Partnership with INC Research
7. Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
8. Bioptix Announces Executive Leadership Change
9. Nerium International announces expansion into New Zealand
10. Charm Sciences Announces New Sales/Business Manager
11. BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
Breaking Biology Technology:
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
Breaking Biology News(10 mins):